Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

April 13, 2011

Biogen Idec’s oral multiple sclerosis candidate, BG-12 (dimethyl fumarate), met its primary endpoint in the first of two Phase III pivotal trials in patients with relapsing-remitting disease

  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
  • Oral MS Medications
    /
April 12, 2011 – Biogen Idec’s oral multiple sclerosis candidate, BG-12 (dimethyl fumarate), met its primary endpoint in the first…
MS Drug Therapies

April 13, 2011

Multiple Sclerosis Cooling Program

  • Additional MS resource sites
    /
  • News from the MS Foundation
    /
More often than not, heat and MS don’t mix. As the body temperature rises, weakness, fatigue, visual disturbances, and other…
Additional MS resource sites

April 13, 2011

New Copaxone® data reported from AAN demonstrate clinical benefits of switching MS patients to Copaxone®.

  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
April 12, 2011 Additional study data show significant improvement of cognition and improved quality of life measures following treatment with…
MS Drug Therapies

April 13, 2011

Potential New MS PIll: Experimental medication slowed the rate of brain atrophy and disease progression and relapse, study found

  • Multiple Sclerosis
    /
  • Oral MS Medications
    /
A new oral medication for the treatment of multiple sclerosis (MS) shows promise in slowing disease progression, limiting brain atrophy…
Multiple Sclerosis

April 13, 2011

MULTIPLE SCLEROSIS & other DIFF. ABILITIES

  • Additional MS resource sites
    /
On September 27th, 2010, one month following her Official Multiple Sclerosis diagnosis, Rae Edwards Founded The 1st Multiple Sclerosis &…
Additional MS resource sites

April 12, 2011

Biogen Idec’s Ongoing Dedication To People Living With MS

  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
April 12, 2011 Biogen Idec  today announced that data highlighting the company’s focus and drive towards addressing the needs of…
MS Drug Therapies

April 12, 2011

Oral Laquinimod For MS Treatment Significantly Reduced Disease Activity And Disability Progression While Providing Good Safety And Tolerability

  • Multiple Sclerosis
    /
  • Oral MS Medications
    /
April 12, 2011 Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study…
Multiple Sclerosis

April 12, 2011

Mayo Clinic Finds Tool To Predict Disability Timeline For Progressive MS Patients

  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
April 12, 2011 Many patients with progressive multiple sclerosis (MS) worry how quickly the disease will progress. Now, by noting the presence…
MS Research Study and Reports

April 11, 2011

Biogen Oral MS Pill Meets Goals of Study

  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
  • Oral MS Medications
    /
April 11, 2011 By THOMAS GRYTA Biogen Idec Inc.’s oral drug for multiple sclerosis showed success in the first of two large…
MS Drug Therapies

April 11, 2011

Media Release: Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of disease severity

  • Oral MS Medications
    /
Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows…
Oral MS Medications

Categories

Latest Blog Posts